We are able to deploy our technologies fully in developing bispecific antibodies, innovative biologics able to bind multiple drug targets that hold a promise of being more effective therapeutic compounds than conventional, monospecific antibodies.
Bispecific antibodies can recognise targets on two different cells, bringing them together such as recruiting immune effector cells to the target cell, so enhancing its destruction. They can also bind two different targets on the same cell, providing enhanced specificity or bridging missing components.
Our technologies provide four key advantages:
- a huge biological diversity of naturally matured antibodies;
- our ability to screen the repertoire deeply;
- our system of in vivo affinity maturation to develop molecules with very high affinity;
- our novel IntelliSelect™ technology deeply mines the human antibody diversity within Kymouse™ to discover the most potent medicines.